Furthermore, in our study, IL-6 was the only predictor of survival and treatment-related mortality, suggesting that IL-6 measurements after haplo-HSCT with PTCy may be useful for predicting both acute GVHD and post-transplant prognosis. Here, IL6 is linked to acute graft versus host disease.